BR112013025845A2 - formulações com viscosidade reduzida - Google Patents
formulações com viscosidade reduzidaInfo
- Publication number
- BR112013025845A2 BR112013025845A2 BR112013025845A BR112013025845A BR112013025845A2 BR 112013025845 A2 BR112013025845 A2 BR 112013025845A2 BR 112013025845 A BR112013025845 A BR 112013025845A BR 112013025845 A BR112013025845 A BR 112013025845A BR 112013025845 A2 BR112013025845 A2 BR 112013025845A2
- Authority
- BR
- Brazil
- Prior art keywords
- low viscosity
- viscosity formulations
- formulations
- low
- viscosity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473123P | 2011-04-07 | 2011-04-07 | |
| PCT/US2012/032464 WO2012141978A2 (en) | 2011-04-07 | 2012-04-06 | Formulations with reduced viscosity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013025845A2 true BR112013025845A2 (pt) | 2018-09-04 |
Family
ID=47009919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013025845A BR112013025845A2 (pt) | 2011-04-07 | 2012-04-06 | formulações com viscosidade reduzida |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140044727A1 (https=) |
| EP (1) | EP2694708A4 (https=) |
| JP (1) | JP2014510152A (https=) |
| KR (1) | KR20140066124A (https=) |
| CN (1) | CN103582724A (https=) |
| AU (1) | AU2012243126A1 (https=) |
| BR (1) | BR112013025845A2 (https=) |
| CA (1) | CA2832560A1 (https=) |
| EA (1) | EA201391489A1 (https=) |
| IL (1) | IL228626A0 (https=) |
| SG (1) | SG193964A1 (https=) |
| WO (1) | WO2012141978A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012501364A1 (en) * | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| EA201590061A1 (ru) * | 2012-06-21 | 2015-05-29 | Юсб Фарма С.А. | Фармацевтическая композиция |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| KR20180037275A (ko) | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| CN105733250B (zh) * | 2016-05-04 | 2017-12-26 | 山东省药学科学院 | 一种交联聚谷氨酸悬浮液及其制备方法与应用 |
| ES2933808T3 (es) * | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
| SI4190355T1 (sl) * | 2017-04-28 | 2025-02-28 | Amgen Inc. | Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| BR112019025736A2 (pt) | 2017-06-06 | 2020-06-30 | Glaxosmithkline Llc | uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CN113660927A (zh) * | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20050164929A1 (en) * | 2000-11-06 | 2005-07-28 | Lupine Logic, Inc. | Methods of preventing and treating inflammatory bowel disease |
| CA2503946C (en) * | 2002-11-01 | 2016-08-16 | Glaxosmithkline Biologicals S.A. | Drying process |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| AU2006296399B2 (en) * | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| EP2205280B1 (en) * | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| BR112012027828A2 (pt) * | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
-
2012
- 2012-04-06 EA EA201391489A patent/EA201391489A1/ru unknown
- 2012-04-06 CA CA2832560A patent/CA2832560A1/en not_active Abandoned
- 2012-04-06 KR KR1020137029164A patent/KR20140066124A/ko not_active Withdrawn
- 2012-04-06 EP EP12771966.4A patent/EP2694708A4/en not_active Withdrawn
- 2012-04-06 JP JP2014504014A patent/JP2014510152A/ja active Pending
- 2012-04-06 SG SG2013072434A patent/SG193964A1/en unknown
- 2012-04-06 BR BR112013025845A patent/BR112013025845A2/pt not_active IP Right Cessation
- 2012-04-06 AU AU2012243126A patent/AU2012243126A1/en not_active Abandoned
- 2012-04-06 US US14/110,252 patent/US20140044727A1/en not_active Abandoned
- 2012-04-06 CN CN201280025770.0A patent/CN103582724A/zh active Pending
- 2012-04-06 WO PCT/US2012/032464 patent/WO2012141978A2/en not_active Ceased
-
2013
- 2013-09-29 IL IL228626A patent/IL228626A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140044727A1 (en) | 2014-02-13 |
| WO2012141978A2 (en) | 2012-10-18 |
| CN103582724A (zh) | 2014-02-12 |
| SG193964A1 (en) | 2013-11-29 |
| EP2694708A2 (en) | 2014-02-12 |
| EP2694708A4 (en) | 2014-10-01 |
| IL228626A0 (en) | 2013-12-31 |
| CA2832560A1 (en) | 2012-10-18 |
| AU2012243126A1 (en) | 2013-10-17 |
| JP2014510152A (ja) | 2014-04-24 |
| WO2012141978A3 (en) | 2012-12-27 |
| KR20140066124A (ko) | 2014-05-30 |
| EA201391489A1 (ru) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013025845A2 (pt) | formulações com viscosidade reduzida | |
| SI3725778T1 (sl) | Formulacije enzalutamida | |
| BR112013017183A2 (pt) | composições de bepostatina | |
| LT2742151T (lt) | Polimerazės kompozicija | |
| BR112013022112A2 (pt) | composição | |
| EP2706981A4 (en) | COSMETIC COMPOSITIONS | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| EP3488847C0 (en) | SEMIFLUORINATED ALKANE COMPOSITIONS | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| BR112014004395A2 (pt) | composição | |
| CO6930368A2 (es) | Composiciones de yodo-povidona estable | |
| EP2673344A4 (en) | STABLE BIO OIL | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| BR112013033808A2 (pt) | composição | |
| BR112014000015A2 (pt) | formulação | |
| HUE040370T2 (hu) | Gyógyszerkészítmények | |
| EP2730619A4 (en) | COMPOSITION | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| EP2881431A4 (en) | Viscous composition | |
| PT2739276T (pt) | Composição antisséptica | |
| EP2739670A4 (en) | COMPOSITIONS FROM SOL-GEL | |
| EP2770828A4 (en) | FORMULATION | |
| BR112014007030A2 (pt) | composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018. |